Fosrenol ODT (Lanthanum Carbonate, BAY77-1931) + Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical Pharmacology
Conditions
Clinical Pharmacology
Trial Timeline
Jun 10, 2015 → Aug 21, 2015
NCT ID
NCT03074058About Fosrenol ODT (Lanthanum Carbonate, BAY77-1931) + Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)
Fosrenol ODT (Lanthanum Carbonate, BAY77-1931) + Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) is a phase 1 stage product being developed by Bayer for Clinical Pharmacology. The current trial status is completed. This product is registered under clinical trial identifier NCT03074058. Target conditions include Clinical Pharmacology.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03074058 | Phase 1 | Completed |
Competing Products
20 competing products in Clinical Pharmacology